Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Beijing Luzhu Biotechnology Co., Ltd.
北京綠竹生物技術股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2480)

VOLUNTARY ANNOUNCEMENT
POSITIVE CLINICAL DATA FOR HEAD-TO-HEAD COMPARISON STUDY OF LZ901

This announcement is made by Beijing Luzhu Biotechnology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders of the Company and potential investors on the latest business updates of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce the positive immunogenicity and safety data in adults aged 50 or above from a randomized, active-controlled and non-inferiority trial of LZ901, the core product of the Group, compared head-to-head with HZ/su vaccine (Shingrix®), a recombinant glycoprotein E (gE) subunit vaccine. In such study, 301 healthy adults aged 50 or above were enrolled and at least 291 healthy adults received either two doses of LZ901 or HZ/su vaccine. The study results showed that LZ901 induced superior cellular immunogenicity and exhibited a better safety profile than HZ/su vaccine in adults aged 50 or above.

Key results of the head-to-head comparison study of LZ901 are summarized below:

Immunogenicity results

- LZ901 demonstrated non-inferiority to HZ/su vaccine (with margin greater than -10%) for both CD4+ and CD8+ T-cells responses, with significantly higher response rates.

- The proportion of gE-specific CD4+ T-cell responders amounted to 83.0% for LZ901 recipients, as compared to 58.1% for HZ/su vaccine recipients.

- The proportion of gE-specific CD8+ T-cell responders amounted 46.8% for LZ901 recipients, as compared to 8.8% for HZ/su vaccine recipients.

Safety & reactogenicity results

- Overall, LZ901 demonstrated better safety and reactogenicity profiles than HZ/su vaccine.

- Lower rates of adverse reactions were observed for LZ901 (41.1%) as compared to HZ/su vaccine (87.9%), with most reported AEs being mild or moderate in severity. Grade 3 adverse reactions were only reported by one of LZ901 recipients (0.7%), as compared to nine of HZ/su vaccine recipients (6.0%).

- Injection-site solicited reactions occurred in 27.2% of LZ901 recipients and in 82.6% of HZ/su recipients ($p < 0.0001$), respectively. The most common injection site adverse reactions were pain (27.2% vs. 80.5%), redness (0.7% vs. 16.8%), swelling (2.7% vs. 16.1%) and pruritus (0 vs. 14.8%), which were all more frequently reported in the HZ/su vaccine group than the LZ901 vaccine group did.

- Systemic solicited reactions were reported by 14.6% of LZ901 recipients and 54.4% of HZ/su recipients ($p < 0.0001$). The most common systemic adverse reactions were fever (1.3% vs. 42.9%), weakness (5.9% vs. 27.5%), headache (1.9% vs. 13.4%), muscle pain (1.3% vs. 12.1%) and fatigue (1.9% vs 11.4%), which were all more frequently reported in the HZ/su vaccine group than the LZ901 vaccine group did.

Further details of the head-to-head comparison study of LZ901 are also published on the ***Nature Communications*** journal[i].

ABOUT LZ901

LZ901 is a recombinant herpes zoster vaccine candidate independently developed by the Group, and is the core product of the Group. LZ901 aims to prevent the occurrence of herpes zoster and related complications caused by herpes zoster, including postherpetic neuralgia for adults aged 40 years and above. As of the date of this announcement, the biologics license application for LZ901 has been accepted and is currently being assessed by the National Medical Products Administration of the People's Republic of China.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that LZ901 will ultimately be successfully developed and marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Beijing Luzhu Biotechnology Co., Ltd.
Mr. KONG Jian
Chairman and Executive Director

Hong Kong, August 18, 2025

As of the date of this announcement, the Board comprises Mr. KONG Jian, Ms. JIANG Xianmin and Ms. ZHANG Yanping as executive Directors; Mr. MA Biao and Mr. KONG Shuangquan as non-executive Directors; and Ms. HOU Aijun, Mr. LEUNG Wai Yip and Mr. LIANG Yeshi as independent non-executive Directors.

[i] For the full text of the article, please refer to https://www.nature.com/articles/s41467-025-62800-z